Hepalink: Enoxaparin Sodium Injection Receives New Manufacturer Approval from EMA
2025-06-17 16:48:31

Hepalink announced that the company recently received an approval notice from the European Medicines Agency (EMA) regarding the addition of a manufacturer of enoxaparin sodium injection. The drug involved in the approval is enoxaparin sodium injection, with the trade name Inhixa, and the dosage form is injection, with specifications including 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 120mg/0.8ml, 150mg/1ml. The new manufacturer is Shenzhen Hepalink Pharmaceutical Group Co., Ltd., and the production site is located at No. 1 Rongtian Road, Kengzi Street, Pingshan District, Shenzhen, China, with an approval number of EMA/VR/262,500. This approval will provide the company with more sufficient production capacity guarantee for further promoting the internationalization strategy of preparations and effectively improve the company's market competitiveness.
VR
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download